J. Nemunaitis
Immunology · 2000–2023
A researcher in the Science corpus: 8 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 15 citations into it
Whom J. Nemunaitis trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- D. Gabrilovich (in Immunology)
Papers from J. Nemunaitis's perspective
Ordered by how strongly the researchers J. Nemunaitis trusts endorse each paper. Same corpus, a different order for every researcher.
- Argonaute2 Is the Catalytic Engine of Mammalian RNAi (Science)
- Variation in the reversibility of evolution (Nature)
- MicroRNA maturation: stepwise processing and subcellular localization (EMBO Journal)
- MicroRNA-Directed Cleavage of HOXB8 mRNA (Science)
- Human Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP (EMBO Journal)
- Expression profiling reveals off-target gene regulation by RNAi
- Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells (Nature)
- Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. (RNA: A publication of the RNA Society)
- Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. (RNA: A publication of the RNA Society)
- Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways (Nature)
Their papers
- A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer (2000) — 1,158 citations
- Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. (2001) — 1,024 citations
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (2023) — 676 citations
- Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. (2009) — 623 citations
- siRNA vs. shRNA: similarities and differences. (2009) — 672 citations
- Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer (2009) — 845 citations
- Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. (2006) — 1,121 citations
- Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. (2000) — 737 citations